MedPath

Pedometers and Walking Tests for Pulmonary Hypertension Patients

Not Applicable
Recruiting
Conditions
Hypertension, Pulmonary
Registration Number
NCT03810482
Lead Sponsor
University Hospital, Montpellier
Brief Summary

Concordance between walking tests and pedometer data may seem like a logical outcome for pulmonary hypertension (PH) patients. However, many individuals have discordant results: results much worse or better during an in-hospital walking test as compared to real life activity.

The primary objective of this study is: to determine variables associated with discordance between the distance walked during an in-hospital 6-minute walking test (6MWT) and the average distance travelled per day (observed over a period of 28 days (2 × 14 days) using a pedometer) among PH patients.

Detailed Description

Secondarily, the discordance between 6MWT results versus total pedometer recorded distance and versus maximum daily pedometer-recorded distance will be similarly studied. The aim of the study is also to search for variables associated with progression free survival. The relationships between pedometer data and self-reported dyspnea variation will be studied. Factorial analysis may be used to study the overall view of variable correlations and patient similarity/dissimilarity.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
70
Inclusion Criteria
  • Patient with idiopathic pulmonary hypertension (PH), familial PH, or PH associated with various pathologies (groups I to IV of the international classification)
  • New York Heart Association (NYHA) severity classes II to IV
  • Incident cases, or prevalent cases with stable disease over the last 3 months
  • Collection of informed written consent
  • Affiliation with or beneficiary of a social security program (health insurance)
  • Outpatient consulting at the hospital on the day of inclusion
  • 6 minute walking test on day of inclusion
Exclusion Criteria
  • Patients protected or unable to give consent according to Article L1121-8 of the French Public Health Code (CSP)
  • Pregnant or lactating women according to article L1121-5 of the CSP
  • Vulnerable persons according to article L1121-6 of the CSP
  • Simultaneous participation in any other research protocol
  • It is impossible to correctly inform the patient (language barrier, etc.)
  • The patient has already been included in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
The patient's discordance category as precisely defined here:74 days

Linear regression is performed for the distance walked during an initial 6 minute walking test (6MWT) and the average distance walked per day according to the pedometer intervention. The residuals from this regression will determine categories:

Category 1 (pedometer high): the 25% of subjects not in category 2 and with higher values for pedometer data

Category 2 (concordance): the 50% of included subjects with the smallest residuals in terms of absolute value.

Category 3 (6MWT high): the 25% of subjects not in category 2 and with higher values for 6MWT data

Secondary Outcome Measures
NameTimeMethod
Coping with Health Injuries and Problems ScaleMonth 3

This questionnaire assesses how the patient responds to health injuries and problems with 32 questions. For each question 5 levels of response are possible from 1 (not at all) to 5 (always).

Multidimensional Fatigue Inventory (MFI)-20 questionnaireMonth 3

This questionnaire assesses the severity of the patient fatigue through 20 questions. For each question, 4 levels of response are possible : from "not at all" to "completely".

Health related quality of life questionnaire (the Medical Outcome Study - Short Form (SF36))Month 3

This scale evaluates social, emotional and physical health of the patient through 11 questions.

Hospital Anxiety and Depression (HAD) scaleMonth 3

It is a questionnaire which detects if the patient is anxious or depressed through 14 questions.

State-Trait Anxiety Inventory (STAI) questionnaireMonth 3

The State-Trait Anxiety Inventory is a 20 question-scale. For each question 4 levels of response are possible from 1 (never) to 4 (always).

Trial Locations

Locations (1)

Arnaud de Villeneuve Hospital

🇫🇷

Montpellier, France

Arnaud de Villeneuve Hospital
🇫🇷Montpellier, France
Arnaud Bourdin, MD, PhD
Principal Investigator
Clement Boissin, MD
Sub Investigator
Anne Sophie Gamez, MD
Sub Investigator
Romain Jean, MD
Sub Investigator
Jérémy Charriot, MD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.